Long-term Dental Anomalies after Pediatric Cancer Treatment in ChildrenGülser Kılınç1, Gülçin Bulut2, Fahinur Ertuğrul3, Hale Ören4, Bengü Demirağ5, Ayşe Demiral6, Serap Aksoylar7, Emine Serra Kamer8, Hülya Ellidokuz9, Nur Olgun101Dokuz Eylül University Faculty of Medicine, Department of Pediatric Dentistry, İzmir, Turkey 2İzmir Training Dental Hospital, Clinic of Pediatric Dentistry, İzmir, Turkey 3Ege University Faculty of Dentistry, Department of Pedodontics, İzmir, Turkey 4Dokuz Eylül University Faculty of Medicine, Department of Pediatric Hematology, İzmir, Turkey 5Behçet Uz Children’s Hospital, Clinic of Pediatric Hematology and Oncology, İzmir, Turkey 6Dokuz Eylül University Faculty of Medicine, Department of Radiation Oncology, İzmir, Turkey 7Ege University Faculty of Medicine, Department of Pediatric Hematology, İzmir, Turkey 8Ege University Faculty of Medicine, Department of Radiation Oncology, İzmir, Turkey 9Dokuz Eylül University, Institute of Oncology, Department of Preventive Oncology, İzmir, Turkey 10Dokuz Eylül University, Institute of Oncology, Department of Pediatric Oncology, İzmir, Turkey
Objective: The aim of this study is to determine the frequency of dental anomalies (DAs) (microdontia, hypodontia, hyperdontia, enamel defect, root malformation) in pediatric cancer patients at the ages <5 years and between 5 and 7 years, and understand their relationship with the received therapy. Materials and Methods: Pediatric patients who were diagnosed with cancer and treated before the age of 7 years were investigated in a case- control design. The study included 93 pediatric patients whose ages at diagnosis were between 9 months and 7 years and whose treatments were completed before 5-8 years. Group A consisted of patients in the age range of 9 months to 4 years and Group B consisted of patients in the age range of 5-7 years. Seventy-two siblings with compatible dental age ranges were included in the control group. For both groups, intraoral examinations were performed and panoramic radiographs were taken. Results: Among the 93 pediatric patients, the mean age was 9.54±1.25 (range: 8-13 years) and 48 (51.6%) patients were male. The most common diagnosis was hematologic malignancy with a rate of 65.5%. At least one DA was detected in 7 (9.7%) individuals of the control group and in 78 (83.9%) of the patient group. While the patients in the study group had all kinds of DAs, those in the control group had only enamel defects. The rates of microdontia (p=0.077) and hypodontia (p=0.058) were detected to be significantly higher in Group A than in Group B. Root malformation was more common in patients receiving chemotherapy and radiotherapy than in those receiving only chemotherapy (p=0.006). Conclusion: In this study it was found that the pediatric patients who received cancer treatment before the age of 7 years constituted a high-risk group for DAs. The frequencies of microdontia and hypodontia were increased even more when the patient was treated for cancer before 5 years of age.
Keywords: Cancer, Children, Dental anomalies, Hypodontia, Microdontia, Root malformation, Enamel defect
Kanser Tedavisi Gören Çocuklarda Uzun Süre Sonra Görülen Diş AnomalileriGülser Kılınç1, Gülçin Bulut2, Fahinur Ertuğrul3, Hale Ören4, Bengü Demirağ5, Ayşe Demiral6, Serap Aksoylar7, Emine Serra Kamer8, Hülya Ellidokuz9, Nur Olgun101Dokuz Eylül University Faculty of Medicine, Department of Pediatric Dentistry, İzmir, Turkey 2İzmir Training Dental Hospital, Clinic of Pediatric Dentistry, İzmir, Turkey 3Ege University Faculty of Dentistry, Department of Pedodontics, İzmir, Turkey 4Dokuz Eylül University Faculty of Medicine, Department of Pediatric Hematology, İzmir, Turkey 5Behçet Uz Children’s Hospital, Clinic of Pediatric Hematology and Oncology, İzmir, Turkey 6Dokuz Eylül University Faculty of Medicine, Department of Radiation Oncology, İzmir, Turkey 7Ege University Faculty of Medicine, Department of Pediatric Hematology, İzmir, Turkey 8Ege University Faculty of Medicine, Department of Radiation Oncology, İzmir, Turkey 9Dokuz Eylül University, Institute of Oncology, Department of Preventive Oncology, İzmir, Turkey 10Dokuz Eylül University, Institute of Oncology, Department of Pediatric Oncology, İzmir, Turkey
Amaç: Çalışmanın amacı <5 ve 5-7 yaş arası kanser tanısı alıp tedavi görmüş hastalarda diş anomalileri (DA) (mikrodonti, hipodonti, hiperdonti, mine kusuru, kök şekil bozukluğu) sıklığını belirlemek ve alınan tedavi ile ilişkini saptamaktır. Gereç ve Yöntem: Kanser tanısı alıp 7 yaş öncesi tedavi görmüş çocuk hastalar olgu kontrol yöntemiyle araştırıldı. Kanser tedavisinin üzerinden en az 5-8 yıl geçmiş, tanı yaşı 9 ay ile 7 yıl arasında değişen, 93 hasta çalışmaya dahil edildi. Grup A 9 ay-4 yaş arasındaki hastalardan, Grup B 5-7 yaş arasındaki hastalardan oluşuyordu. Kontrol grubu olarak hastaların yaş aralığı uygun 72 kardeşi alındı. Hasta ve kontrol grubunun ağız içi muayeneleri yapıldı ve panoramik radyografileri alındı. Bulgular: Doksan üç hastanın yaş ortalaması 9,54±1,25 (dağılım 8-13 yıl) ve 48’i (%51,6) erkekti. En sık rastlanan tanı, %65,5 oranında hematolojik malignitelerdir. En az bir tane DA, hasta grubunun 78’inde (%83,9) ve kontrol grubunun 7’sinde (%9,7) saptandı. Çalışma grubundaki hastalarda her çeşit DA görülürken, kontrol grubunda sadece mine kusuru vardı. Grup A’da mikrodonti (p=0,077), hipodonti (p=0,058) oranlarının, Grup B’ye göre daha yüksek olduğu saptandı. Kök şekil bozukluğu kemoterapi ve radyoterapi alan hastalarda sadece kemoterapi alanlara göre daha fazla görüldü (p=0,006). Sonuç: Bu çalışmada 7 yaşından önce kanser tedavisi gören hastaların DA’lar yönünden yüksek riskli grup oluşturduğu saptanmıştır. Hastalar 5 yaşından önce kanser tedavisi gördüğünde mikrodontia ve hipodontinin sıklığı daha da artmıştır.
Anahtar Kelimeler: Kanser, Çocuk, Diş anomalileri, Hipodonti, Mikrodonti, Kök şekil bozukluğu, Mine defektleri
Gülser Kılınç, Gülçin Bulut, Fahinur Ertuğrul, Hale Ören, Bengü Demirağ, Ayşe Demiral, Serap Aksoylar, Emine Serra Kamer, Hülya Ellidokuz, Nur Olgun. Long-term Dental Anomalies after Pediatric Cancer Treatment in Children. Turk J Hematol. 2019; 36(3): 155-161
Corresponding Author: Gülser Kılınç |
|